Literature DB >> 25133036

Risk of cardiovascular disease in inflammatory bowel disease.

Nynne Nyboe Andersen1, Tine Jess1.   

Abstract

Abundant scientific evidence supporting an association between inflammatory bowel disease (IBD) and venous thromboembolic events, caused by an IBD related hypercoagulability, is acknowledged and thromboprophylactic treatment strategies are now implemented in the management of IBD patients. In contrary, the risk of arterial thromboembolic disease, as ischemic heart disease, cerebrovascular events, and mesenteric ischemia in patients with IBD remains uncertain and the magnitude of a potentially increased risk is continuously debated, with ambiguous risk estimates among studies. The evident role of inflammation in the pathogenesis of atherosclerosis forms the basis of a biological plausible link; the chronic systemic inflammation in IBD patients increases the risk of atherosclerosis and thereby the risk of thrombotic events. Further, studies have shown that the burden of traditional risk factors for atherosclerosis, such as obesity, diabetes mellitus, and dyslipidemia is lower in IBD populations, thus further strengthen the role of non-traditional risk factors, as chronic inflammation in the linking of the two disease entities. Likewise, mortality from cardiovascular disease in IBD remains questioned. The aim of the current review is to give an up-date on the existing evidence of the possible association between IBD and cardiovascular disease and to discuss traditional and non-traditional risk factors.

Entities:  

Keywords:  Crohn’s disease; Inflammatory bowel disease; Risk; Ulcerative colitis; cardiovascular disease

Year:  2014        PMID: 25133036      PMCID: PMC4133533          DOI: 10.4291/wjgp.v5.i3.359

Source DB:  PubMed          Journal:  World J Gastrointest Pathophysiol        ISSN: 2150-5330


  51 in total

1.  Vascular complications of inflammatory bowel disease.

Authors:  R W Talbot; J Heppell; R R Dozois; R W Beart
Journal:  Mayo Clin Proc       Date:  1986-02       Impact factor: 7.616

2.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.

Authors:  Matthew J Grainge; Joe West; Timothy R Card
Journal:  Lancet       Date:  2010-02-08       Impact factor: 79.321

3.  Inflammatory bowel disease is associated with an increased incidence of cardiovascular events.

Authors:  Andres J Yarur; Amar R Deshpande; David M Pechman; Leonardo Tamariz; Maria T Abreu; Daniel A Sussman
Journal:  Am J Gastroenterol       Date:  2011-03-08       Impact factor: 10.864

4.  Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

Authors:  Jeffrey D Greenberg; Joel M Kremer; Jeffrey R Curtis; Marc C Hochberg; George Reed; Peter Tsao; Michael E Farkouh; Adeel Nasir; Soko Setoguchi; Daniel H Solomon
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

5.  Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.

Authors:  Seth D Crockett; Richard A Hansen; Til Stürmer; Robin Schectman; Jane Darter; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2011-08-08       Impact factor: 5.325

6.  Venous thromboembolism in inflammatory bowel disease.

Authors:  Craig A Solem; Edward V Loftus; William J Tremaine; William J Sandborn
Journal:  Am J Gastroenterol       Date:  2004-01       Impact factor: 10.864

7.  Prothrombin fragment 1 + 2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases.

Authors:  P Chamouard; L Grunebaum; M L Wiesel; P L Frey; C Wittersheim; R Sapin; R Baumann; J P Cazenave
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-12       Impact factor: 2.566

8.  Evidence of endothelial dysfunction in patients with inflammatory bowel disease.

Authors:  Idan Roifman; Yichun C Sun; Jason P Fedwick; Remo Panaccione; Andre G Buret; Hongqun Liu; Alaa Rostom; Todd J Anderson; Paul L Beck
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10-30       Impact factor: 11.382

9.  Ischemic stroke and peripheral arterial thromboembolism in a patient with Crohn's disease: a case presentation.

Authors:  Tobias Freilinger; Eva Riedel; Markus Holtmannspötter; Martin Dichgans; Nils Peters
Journal:  J Neurol Sci       Date:  2007-09-27       Impact factor: 3.181

10.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

View more
  10 in total

1.  Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner.

Authors:  Matthew Stephens; Pierre-Yves von der Weid
Journal:  Gut Microbes       Date:  2019-06-16

Review 2.  Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.

Authors:  Dorota Cibor; Renata Domagala-Rodacka; Tomasz Rodacki; Artur Jurczyszyn; Tomasz Mach; Danuta Owczarek
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Associations of Bowel Movement Frequency with Risk of Cardiovascular Disease and Mortality among US Women.

Authors:  Wenjie Ma; Yanping Li; Yoriko Heianza; Kyle D Staller; Andrew T Chan; Eric B Rimm; Kathryn M Rexrode; Lu Qi
Journal:  Sci Rep       Date:  2016-09-06       Impact factor: 4.379

Review 4.  Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

Authors:  Paul Welsh; Gianluca Grassia; Shani Botha; Naveed Sattar; Pasquale Maffia
Journal:  Br J Pharmacol       Date:  2017-06-10       Impact factor: 8.739

Review 5.  Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.

Authors:  Robin J Dart; Mark A Samaan; Nick Powell; Peter M Irving
Journal:  Clin Exp Gastroenterol       Date:  2017-03-03

6.  Obesity Downregulates MicroRNA-126 Inducing Capillary Rarefaction in Skeletal Muscle: Effects of Aerobic Exercise Training.

Authors:  João Lucas Penteado Gomes; Tiago Fernandes; Ursula Paula Reno Soci; André Casanova Silveira; Diego Lopes Mendes Barretti; Carlos Eduardo Negrão; Edilamar Menezes Oliveira
Journal:  Oxid Med Cell Longev       Date:  2017-03-06       Impact factor: 6.543

Review 7.  Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review.

Authors:  Kenneth M Borow; R Preston Mason; Krishnaswami Vijayaraghavan
Journal:  Cardiorenal Med       Date:  2017-09-16       Impact factor: 2.041

8.  Long-term risk of cardiovascular and cerebrovascular disease after removal of the colonic microbiota by colectomy: a cohort study based on the Danish National Patient Register from 1996 to 2014.

Authors:  Anders Boeck Jensen; Teresa Adeltoft Ajslev; Søren Brunak; Thorkild I A Sørensen
Journal:  BMJ Open       Date:  2015-12-15       Impact factor: 2.692

9.  Development of Inflammatory Bowel Disease Is Linked to a Longitudinal Restructuring of the Gut Metagenome in Mice.

Authors:  Thomas Sharpton; Svetlana Lyalina; Julie Luong; Joey Pham; Emily M Deal; Courtney Armour; Christopher Gaulke; Shomyseh Sanjabi; Katherine S Pollard
Journal:  mSystems       Date:  2017-09-05       Impact factor: 6.496

Review 10.  Cannabinoids and Inflammations of the Gut-Lung-Skin Barrier.

Authors:  Cristian Scheau; Constantin Caruntu; Ioana Anca Badarau; Andreea-Elena Scheau; Anca Oana Docea; Daniela Calina; Ana Caruntu
Journal:  J Pers Med       Date:  2021-05-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.